NovoCure Ltd. NVCR

What this company does

NovoCure is a global oncology company with a proprietary platform technology called Tumor Treating Fields, which are electric fields that exert physical forces to kill cancer cells, delivered through a medical device. As of December 31, 2025, it had 1,605 employees, compared to 1,488 employees as of December 31, 2024. It markets its products in multiple countries around the globe, with the majority of its revenues coming from the use of Optune Gio in the U.S., Germany, France and Japan. It offers Optune Gio, Optune Lua and Optune Pax as its commercial TTFields therapy devices. Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, and for adult patients with glioblastoma following confirmed recurrence after chemotherapy as monotherapy treatment. Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen. Optune Pax is approved by the FDA under the PMA pathway for the treatment of adult patients with locally advanced pancreatic cancer concurrent with gemcitabine and nab-paclitaxel. NovoCure was incorporated in the Bailiwick of Jersey in 2000.

Written from the business description in NovoCure Ltd's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.